Clinical Trial

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Study acronym: ziMyG
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2023-09-20; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2024-03-06
Trial Details
NCT Number NCT06055959
Lead Sponsor UCB Biopharma SRL
Conditions Generalized Myasthenia Gravis
Enrollment 8 participants
Start Date 2024-10-16
Primary Completion 2026-11-16 (estimated)
Study Completion 2026-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-31